The integration of artificial intelligence into dermatology is revolutionizing the early detection and diagnosis of skin cancers. Recent advancements suggest that AI can serve as a valuable adjunct to traditional
The U.S. Food and Drug Administration (FDA) recently issued an alert regarding compounded topical finasteride products, warning health care providers, compounders, and consumers about potentially serious risks associated with their
The U.S. Food and Drug Administration (FDA) has approved ZEVASKYN™ (prademagene zamikeracel), marking a historic milestone as the first and only autologous cell-based gene therapy for the treatment of wounds
Allergan Aesthetics, an AbbVie company, has announced the launch of an innovative Skin Quality Index—a universal vocabulary for skin quality designed to improve patient-provider communication and treatment outcomes. The initiative
The International League of Dermatological Societies (ILDS) recently published an updated position statement addressing the concerning rise in the misuse of topical corticosteroids as skin-bleaching products. Describing the issue as
A recent study has identified obesity as a significant contributor to the reduced long-term efficacy of biologic therapies in patients with severe plaque psoriasis, highlighting the need for more personalized
Molecular Instruments®, Inc. (MI), a leading innovator in bioimaging, has announced a major breakthrough in skin disease diagnostics. In collaboration with the Department of Dermatology at Yale School of Medicine,
Chronic hand eczema (CHE) is an often-overlooked skin condition that affects nearly 15.9 million people in the United States. Despite its prevalence, many healthcare providers struggle to fully comprehend the
During a recent investigation, the U.S. Food and Drug Administration (FDA) conducted testing on 95 acne products containing benzoyl peroxide to assess potential benzene contamination. The results, released on March
L’Oréal has voluntarily recalled all lots of its acne treatment, Effaclar Duo, in the U.S. due to concerns that the product may be contaminated with benzene, a known carcinogen. Effaclar
Research has shown that individuals with darker Fitzpatrick skin types (III-VI) face a higher risk of developing post-inflammatory hyperpigmentation (PIH). According to studies, this increased susceptibility is due to larger
Alphyn has announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for Zabalafin Hydrogel, a groundbreaking treatment for mild-to-moderate atopic dermatitis (AD).
A potential new treatment for bullous pemphigoid (BP) is on the horizon as the U.S. Food and Drug Administration (FDA) grants priority review to Dupixent’s (dupilumab) supplemental biologics license application
Galderma recently announced the results of its clinical trial exploring the benefits of combining Restylane® Lyft™ or Contour™ with Sculptra® in patients experiencing facial volume loss due to medication-driven weight
DELTA TEEN is a phase 3 clinical trial by LEO Pharma that evaluated Anzupgo® (delgocitinib) 20mg/g cream for adolescents with moderate-to-severe chronic hand eczema (CHE). The trial demonstrated positive results
During a recent phase 2 study, researchers revealed that a combination of baricitinib and narrowband UV-B therapy significantly improved both disease activity and quality of life for individuals living with
Fesarius Therapeutics Inc. recently announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its DermiSphere Hydrogel Dermal Regeneration Template (DermiSphere hDRT). This innovative product represents
Although cosmetic treatments have traditionally been geared more towards the adult population, current data reveals a growing trend in cosmetic procedures among pediatric patients. This study aimed to explore the
Research conducted over the years has led to the discovery of the axolotl salamanders (Ambystoma mexicanum) and their remarkable regenerative abilities. These findings offer promising insights for regenerative medicine, skin
In a recent press release, Bristol Myers Squibb announced the positive results of their pivotal Phase 3 trials (POETYK PsA-1 and POETYK PsA-2) evaluating the safety and efficacy of Sotyktu
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
LiVDerm / South Beach Symposium
1801 N Military Trail, Ste 110
Boca Raton, FL, 33431
Copyright © 2025, LiVDerm. All Rights Reserved.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
